AbTherx
Justin Mika is an experienced executive in the biopharmaceutical field, currently serving as the Chief Executive Officer of AbTherx, a company focused on advancing therapeutic antibody discovery. Before this role, Justin was the Chief Executive Officer of AlivaMab Discovery Services and held senior leadership positions at Eurofins Discovery and Eurofins DiscoverX, where responsibilities included strategic direction and management of global operations. Justin is also a Board Member at PhenoVista Biosciences, contributing to the development of advanced phenotypic assay services. Academic credentials include a Bachelor of Science in Science with a focus on Biochemistry and Molecular Biology from Penn State University, a Master of Science in Organizational Development, and an MBA from the University of Delaware.
This person is not in any teams
AbTherx
AbTherx is advancing medicine with revolutionary technologies that accelerate and enable therapeutic antibody discovery. Through an exclusive partnership with Gilead Sciences, AbTherx has released Atlas™ Mice, a suite of novel transgenic technologies designed for unmatched performance and FTO. For over 20 years, AbTherx’s passionate, innovative, and collaborative team has pushed the boundaries of antibody discovery technologies, leading to over 1,000 successful antibody discovery campaigns and 13 marketed therapeutics. AbTherx’s industry-leading team creates transformative solutions to overcome the most demanding challenges in delivering innovative medicines. Committed to making its technologies accessible to all, AbTherx offers flexible partnering models that meet the needs of drug developers of all sizes.